The I-MAMMO Study: Surveillance Mammography for Older Breast Cancer Survivors
This study, called I-MAMMO, is for women aged 80 and older who have had breast cancer (stages 0-III) but no recurrence. It's testing a "Shared Decision-Making Toolkit" (SDM toolkit). This toolkit helps you and your doctor talk about whether to continue getting mammograms to check for new cancer. The study wants to see if using this toolkit changes how many women get mammograms after two years. The study aims to enroll 364 participants.
- Study design
- This study is interventional and will enroll 364 participants. You will be placed into one of two groups: either receiving usual care or using the SDM Toolkit, based on your assigned clinician's group.
- What's involved
- You will complete questionnaires and have interviews with study staff. Your participation in this research study is expected to last about 2 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your mammography rate will be assessed at 2 years post-enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07123649
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
Recruiting
PHASE2Ages 80+InterventionalHealth servicesDana-Farber Cancer InstituteInvestigator-initiated
~364 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Shared Decision-Making Toolkit
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mammography Rate
Measured over Assessed at 2 years post-enrollment.
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Study leadership
- Rachel Freedman, MD, MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Women aged ≥ 80 years at the time of registration
History of stage 0-III breast cancer (Of note: ductal carcinoma in situ \[DCIS\], pleomorphic lobular carcinoma in situ \[because it is typically treated like DCIS\], or invasive breast cancer of any subtype are all eligible)
No history of a recurrent breast cancer (i.e., a breast cancer that is deemed metastatic or a locoregional recurrence of a prior cancer per clinician judgement rather than a new primary breast cancer). If a person has been diagnosed with multiple distinct breast cancers over time (e.g., history of left and right breast cancer), they are eligible as long as they meet other requirements for time since surgery, etc.
Has at least one intact breast
Has had mammogram screening/surveillance within the last 24 months
≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)
No active cancer-directed therapy other than hormonal therapy and/or CDK 4/6 inhibitor therapy
Ability and willingness to take surveys
Receiving at least some of their oncology follow-up care at a participating site
Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging
If a patient required diagnostic breast testing in the past or at the time of the most recent mammogram AND the results were resolved to benign findings with no additional diagnostics recommended, they are eligible.
If a patient's most recent mammogram result isn't yet available at the time of approach or study consent, the patient is eligible to proceed with consent and enrollment. If this mammogram then abnormal or requires additional imaging, that patient will not be included in the study analyses or surveys. This patient will be replaced.
Must be an active clinician (MD, NP, or PA) at a participating institution
Sees at least one breast-cancer survivor aged ≥ 80
Clinician must be able to read, speak, and write in English
Exclusion
Inability to provide informed consent
Assigned male sex at birth
Breast or recent imaging findings requiring diagnostic testing at baseline
Prior discontinuation of mammography by electronic medical record (EMR) review or patient report
Prior atypical ductal hyperplasia (ADH) or non-pleomorphic LCIS only
Psychiatric illness situations that would limit compliance with study requirements
Those with metastatic breast cancer
Those in hospice care
Those whose clinician is not willing to participate
Pregnant women, young patients, and those in prison will not be eligible for enrollment given the study design and aims supporting study in a different population focused on older adults
What this trial measures
- Mammography RateAssessed at 2 years post-enrollment.
Mammography Rate is defined as the proportion of participants that undergo mammography by 2 years post-enrollment.